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INTRODUCTION 
Unstable angina and Non ST segment elevation myocardial infarction 
[NSTEMI] remain leading causes of morbidity and mortality worldwide. These 
conditions are part of a continuum of acute coronary syndromes that ranges 
from unstable angina and NSTEMI to ST segment elevation Myocardial 
infarction [STEMI].  
Acute total occlusion of a coronary artery usually causes STEMI 
whereas UA/NSTEMI usually results from severe obstruction but not total 
occlusion of the culprit coronary artery.  
The definition of Unstable angina is largely based on clinical 
presentation. Stable angina pectoris typically manifests as a deep, poorly 
localized chest or arm discomfort, reproducibly precipitated by physical 
exertion or emotional stress and relieved within 5 to 15 minutes by rest and/or 
sublingual nitro-glycerine. 
In contrast, unstable angina is defined as angina pectoris or equivalent 
type of ischaemic discomfort with at least one of the three features: 1] 
occurring at rest and usually lasting more than 20 minutes [If not interrupted by 
nitro-glycerine administration] 2] being severe and described as frank pain, and 
of new onset [i.e., within 1 month] and 3] occurring with a crescendo pattern 
[i.e., more severe, prolonged or frequent than previously]. Of this group, 
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NSTEMI is distinguished from UA by the presence of elevated serum levels of 
cardiac biomarkers. 
The putative theory is that the clinical syndrome of unstable angina is 
caused by rupture of the atherosclerotic plaque with superimposed thrombus 
formation.  It is characterised by angiographically complex coronary lesions in 
the majority of patients1. This anatomy often portends high morbidity2. 
Inflammation has been implicated in the pathophysiology of vulnerable 
coronary plaques. This is evident from histological studies of coronary lesions 
demonstrating abundant inflammatory infiltrates in unstable compared to stable 
plaques.3-8 Furthermore, the local inflammatory process in the coronary arteries 
seem to be expressed systemically by a rise in the levels of acute phase 
reactants and cytokines.  C reactive protein is a sensitive early marker of 
inflammation and has been shown to raise several thousand folds in the 
presence of an inflammatory process in the body.9, 10  
Several studies have examined the association of CRP with acute 
coronary syndromes. C reactive protein rise has been reported before11 as well 
as during unstable angina episodes 12even in the absence of evidence of 
myocardial injury.13 The CRP rise is unlikely to be related to ischemia 
reperfusion injury, since it was absent in patients with the variant angina.14 
Clinically, it appears that elevated CRP predicts a poor prognosis in the 
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patients with unstable angina, reflected by increased incidence of adverse 
ischaemic cardiac events. 15-17 
A new paradigm has emerged suggesting a strong link between CRP 
levels and inflammatory activity in the culprit lesion. This study was designed 
to explore the correlation of CRP levels with the degree of culprit lesion 
angiographic complexity in an unselected group of patients with unstable 
angina. Still there are controversies in regard to management whether to 
undergo early invasive or conservative strategy. Guidelines suggest 
conservative treatment with stabilised patients and among them identifying 
high-risk category based upon risk factors and planning invasive strategy 
suggested. 
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AIM 
This study aims at usefulness of hs CRP in the identification of complex 
culprit lesion anatomy in unstable angina patients and thereby identifies high 
risk category for early revascularisation. 
The following parameters were analysed 
1. Quantification of hs CRP in clinically high risk patients with UA 
2. Analysing Clinical profile of Unstable angina patients with 
reference to hs CRP 
3. To identify any correlation between severity of  coronary artery 
disease with that of hs CRP levels 
4. To study clinical outcome and correlation of hs CRP levels in the 
study population.    
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REVIEW OF LITERATURE 
An etiologic approach has been proposed.18 Five pathophysiological 
processes may contribute to the development of UA/NSTEMI. These include 
1] plaque rupture or erosion with superimposed nonocclusive thrombus [by far 
the most common cause of UA/NSTEMI 2] dynamic obstruction [i.e., coronary 
spasm of an epicardial coronary artery or constriction of the small muscular 
coronary arteries 3] progressive mechanical obstruction 4] inflammation and 5] 
secondary unstable angina, related to increased myocardial oxygen demand or 
decreased supply.  Individual’s patients may have several of these processes 
coexisting as the cause of their episode of UA/NSTEMI. 
The Pathophysiology of UA/NSTEMI involves a broad timeline with 
three phases rather than an isolated ischaemic event. Eventhough traditionally 
focus is on acute event, but pathophysiology may actually begin several 
decades before the acute clinical event, and then may span more than 20 years 
afterward. 
The central role of coronary artery thrombosis in the pathogenesis of 
UA is supported by following observations 1] at autopsy, thrombi usually 
localize at the site of a ruptured or eroded coronary plaques 19 2] high incidence 
of thrombotic lesions detected during coronary atherectomy specimens 3] 
coronary angiography frequently visualizes thrombus 4] coronary angiography 
has demonstrated ulceration or irregularities suggesting a ruptured plaque and 
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or thrombus in many patients 5] elevation of several markers of platelet activity 
and fibrin formation 6] improvement in clinical outcome by antithrombotic 
therapy. 
Rupture of ulceration of an atherosclerotic plaque often exposes the 
subendothelial matrix to circulating blood results in platelet adhesion followed 
by platelet activation due to conformational changes in the shape of platelets 
and provides more surface area for platelet aggregation and release of platelet 
mediators thrombaxane A2, serotonin and others and the finial end result is 
platelet plug. Simultaneously with formation of platelet plug, plasma 
coagulation system activated. Tissue factor triggers and results in activation of 
Factor X and generates thrombin.  Thrombin inturn coverts fibrinogen to fibrin 
and stimulates platelet aggregation and stabilizes fibrin clot.  Factors that 
contribute to plaque instability include lymphocyte and macrophage activation 
and increased inflammation. Infection with chlamydia pneumoniae also may be 
involved.20 
Vasospasm can be induced by the local production of vasoactive 
substances released from the subendothelial matrix or propagating thrombus or 
it can occur as a primary phenomenon. Severe localised spasm of a coronary 
artery segment may also result in ACS. This vasospasm frequently occurs at 
the site of unstable plaque and is thought to contribute to thrombus formation. 
Even angiographically normal coronary arteries with underlying endothelial 
dysfunction may be subject to vasospasm. 
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Unstable can also result from a supply demand mismatch of oxygen 
delivery to the myocardium. With stable obstructive coronary lesions, 
precipitants of unstable angina include increased myocardial oxygen demand 
[i.e., tachy cardia, severe hypertension, cocaine use, hyperthyroidism, fever, or 
sepsis] and decreased oxygen supply [i.e., anaemia or hypoxemia]. 
Clinical characteristics indicative of high risk include acceleration of 
ischaemic symptoms within the preceding 48 hours, angina at rest more than 20 
minutes, congestive heart failure as evidenced by S3 gallop, pulmonary 
oedema, rales, known reduced left ventricular function, hypotension, new or 
worsening mitral regurgitation murmur, age more than 75 years, diffuse ST 
segment changes on an electrocardiogram and the presence of elevated cardiac 
biomarkers[typically creatine kinase MB, troponin T, or troponin I].  Patients at 
intermediate or low risk have angina of short duration, no ischaemic ST-
segment changes on ECG, are negative for cardiac biomarkers and are 
hemodynamically stable.21 
The likelihood of significant coronary artery disease in patients 
presenting with chest pain syndrome is as follows: 22 
• High likelihood (includes any of the following features): 
o History of prior myocardial infarction, sudden death, or other 
known history of coronary artery disease 
o Chest or left arm pain consistent with prior documented 
angina 
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o Transient hemodynamic or ECG changes during pain 
o ST-segment elevation or depression 1 mm or more 
o Marked symmetrical T-wave inversion in multiple precordial 
leads 
• Intermediate likelihood (includes absence of high likelihood features, 
but one of these risk characteristics is present): 
o Age older than 70 years 
o Male sex 
o Diabetes mellitus 
o Extracardiac vascular disease (peripheral, brachiocephalic, or 
renal artery atherosclerosis) 
o ST depression 0.05-1 mm 
o T-wave inversion 1 mm or greater in leads with dominant R 
waves 
• Low likelihood (includes absence of high or intermediate likelihood 
features and any of the following): 
o Chest pain classified as probably not angina 
o Chest discomfort reproduced by palpation 
o T-wave flattening or inversion less than 1 mm in leads with 
dominant R waves 
o Normal ECG findings 
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Risk stratification (Prognosis) 
After the likelihood for coronary artery disease is determined to be 
significant, the next step is to stratify the patient's risk for an event. The 
estimation of likelihood of significant coronary artery disease is critical for 
identifying high-risk patients who may benefit from more aggressive treatment 
strategy (i.e., cardiac catheterization). 
The TIMI Risk Score for unstable angina/NSTEMI is currently the best-
validated prognostic instrument that is simple enough to use in an emergency 
department setting.23 
The presence of any of the following variables constitutes 1 point, with 
the sum constituting the patient risk score on a scale of 0-7: 
• Aged 65 years or older 
• Use of aspirin in the last 7 days 
• Known coronary stenosis of 50% or greater 
• Elevated serum cardiac markers 
• At least 3 risk factors for coronary artery disease (including diabetes 
mellitus, active smoker, family history of coronary artery disease, 
hypertension, hypercholesterolemia) 
• Severe anginal symptoms (2 or more anginal events in the last 24 h) 
• ST deviation on ECG 
10 
Of note, studies have shown that ongoing congestive heart failure, 
presence/history of poor left ventricular ejection fraction (LVEF), 
hemodynamic instability, recurrent angina despite intensive anti-ischemic 
therapy, new or worsening mitral regurgitation, or sustained ventricular 
tachycardia are significant prognosticators for poor outcome. However, these 
factors were not evaluated in the TIMI Risk Score model and should be taken 
into consideration when the level of care is decided. 
Factors that were specifically examined but were not found to have 
prognostic value in the multivariate model include prior myocardial infarction, 
previous percutaneous transluminal coronary angioplasty (PTCA) or coronary 
artery bypass graft, or history of congestive heart failure. 
The inflection point for death or myocardial infarction starts at a TIMI 
Risk Score of 3. Therefore, patients with a score of 3-7 should be considered 
for use of intravenous glycoprotein IIb/IIIa agents, heparin (low molecular 
weight or unfractionated), and early cardiac catheterization  
Classification of unstable angina 
The number and diversity of clinical conditions that cause the transient 
myocardial ischemia of unstable angina along with its varying intensity and 
frequency of pain have made classification within this disorder difficult. 
11 
The Braunwald classification 24 is conceptually useful because it factors 
in the clinical presentation (new or progressive vs rest angina), context 
(primary, secondary, or post–myocardial infarction), and intensity of 
antianginal therapy. 
Braunwald Classification of Unstable Angina24 
Characteristic Class/Category Details 
Severity I Symptoms with exertion 
II Subacute symptoms at rest 
(2-30d prior) 
III Acute symptoms at rest  
(within prior  48 h) 
Clinical precipitating factor A Secondary 
B Primary 
C Postinfarction 
Therapy during symptoms 1 No treatment 
2 Usual angina therapy 
3 Maximal therapy 
 
Patients in class I have new or accelerated exertional angina, whereas 
those in class II have subacute (>48 h since last pain) or class III acute (<48 h 
since last pain) rest angina. The clinical circumstances associated with unstable 
angina are categorized as (A) secondary (anemia, fever, hypoxia), (B) primary, 
or (C) postinfarction (<2 wk after infarction). Intensity of antianginal therapy is 
subclassified as (1) no treatment, (2) usual oral therapy, and (3) intense 
therapy, such as intravenous nitroglycerin. 
12 
Cardiovascular events develop unpredictably in patients with widely 
varying degrees of atherosclerotic disease. The advancement of 
pathophysiology of atherosclerotic vascular diseases has brought new insight 
regarding potential indicators of underlying hidden atherosclerosis and 
cardiovascular risk. Now a days attention has been focused in various novel 
inflammatory markers, especially C reactive protein. Over the last couple of 
decades it has been proved hat CRP is the most reliable marker of 
inflammation. It is 1,35,000 Dalton  non-immunoglobin protein, having five 
identical subunit. The name of the CRP derives from the facts that it reacts with 
capsular polysaccharide of streptococcus pneumoniae.  It is now known that 
CRP specifically recognizes phosphocholine, the hydrophilic part of 
phosphatidyl choline of the cell membranes, complexion of the CRP to the cell 
wall activates complement via classical pathway thus stimulating macrophage 
and other cells to undergo phagocytosis. 
High concentration of hs CRP found in the various conditions: 
Coronary artery disease – unstable angina, myocardial infarction 
 Endocarditis Obesity 
 Sepsis Smoking 
 Vasculitis Allograft vasculopathy and graft occlusion 
 Connective tissue disease – systemic lupus erythematosus, Wegner’s 
granulomatosis 
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Various recent studies have proved that, quantification of CRP is 
superior to cytokine assays of interleukin-6, interleukin b1, and tumor necrosis 
factor for detecting the presence of inflammation in intensive care patients. 
Previously, assay for CRP had a sensitivity of about 5mgm/dl.  By this 
assay, its level was detectable only during significant inflammation in most of 
the individual. 
Recent available high sensitivity assay of CRP have allowed studies to 
be performed on the CRP level of individuals who are apparently healthy.25 
Various study have proved that certain pathogen notably 
cytomegalovirus, chlamydia pneumoniae, helicobacter pylori are associated 
with atherogenesis and development of clinically relevant CAD, perhaps via 
induction of vascular inflammation. 26Zhu and colleagues demonstrated that a 
link between anti CMV antibodies and high CRP level in patients with both an 
elevated CRP level and seropositivity to CMV versus patients with CMV 
seropositivity alone. This finding suggests that CMV contributes to 
atherogenesis by provoking an inflammatory response. Further studies have 
confirmed that risk of angiographically documented CAD and magnitude of 
increase in CRP levels are associated with an increased pathogen burden.27 
This association emphasizes the role of the inflammatory response and host 
defense mechanism in atherosclerosis. 
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Several studies have shown that measurement of hs CRP either at 
admission or at discharge in patients of acute coronary syndrome have 
prognostic value.  Liuzzo et al 14 showed that patients with severe unstable 
angina in absence of myocardial necrosis, hs CRP concentration more than 
3mgm per liter at admission were associated with increased incidence of 
recurrent angina, coronary revascularisation, Myocardial infarction and 
cardiovascular death. Some group later demonstrated that hs-CRP more than 
3mgm per liter at discharge in 53 patients of unstable angina was associated 
with increased readmission for recurrent ischemia and MI. 
Ferreiros et al concluded that prognostic value of hs-CRP measured at 
discharge was better than determined at admission in predicting adverse 
outcome at 90 days.28 
Thrombolysis in myocardial infarction [TIMI 11A] study demonstrated 
that in UA & NSTEMI patients, markedly increased hs-CRP more that 
15mgms/L at presentation in 437 patients was a good predictor of 14 days 
mortality.  Furthermore hs-CRP help to identify those patients with negative 
troponin who were at increased risk of mortality.29 
Recent study by DL Weiner et. al 29 showed that hs-CRP more than 
5mgm per liter at admission in 150 patients with NSTEMI acute coronary 
syndrome were associated with an increased incidence of major cardiac events 
within 6 month regardless of troponin values. 
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CRP level correlate with clinical severity of CAD and coronary events 
in both acute and sub acute phases of myocardial ischemia. UA patients with hs 
CRP more than 3mgm per liter have more ischaemic events in hospital than 
patients with lower CRP levels.  CRP level are significantly lower in patients 
with stable angina than in those with UA and MI patients.  
Bazzino et al compared the prognostic value of stress test and CRP after 
medical stabilization of UA and it showed that elevated CRP levels associated 
with adverse events, when compared with stress testing. Moreover an elevated 
hs-CRP level at time of hospital discharge appears to be amore sensitive and 
specific test markers for increased risk than a positive stress test.30 
The Electrocardiogram 
The ECG is too often overlooked as a powerful risk stratification tool in 
patients with UA/NSTEMI. Even minor ST depression (>0.5 mV) is associated 
is associated with a markedly increased mortality rate. Among 9461 patients 
enrolled in the PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: 
Receptor Suppression Using Integrilin Therapy) study, mortality at 30 days 
was 5.1 percent in patients with ST depression versus 2.1 percent among those 
without ST depression.31 Patients with isolated T-wave inversion have a more 
favourable prognosis than do those with ST depression.32 
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Biochemical Markers 
            Troponin measurements should be used in the risk stratification of 
patients with UA/NSTEMI to supplement the assessment from clinical and 
ECG data. Elevated troponin levels strongly predict coronary events over the 
short-term. The combination of troponin elevation and ST-segment depression 
identifies a group at particularly high risk.33, 34 Measuring troponin not just at 
baseline but also at 8 to 16 hours after admission adds useful prognostic 
information.33 
Coronary angiographic trials have demonstrated that in patients with 
ACS, troponin elevation is associated with multivessel coronary disease, 
complex lesion morphology, and visible thrombus, as well as with impairment 
in microvascular function, which is indicative of distal embolization of plaque 
material and platelet thrombus to the coronary microcirculation. These findings 
have been confirmed using intravascular ultrasound35 and explain the 
consistent association between troponin elevation, even at low levels, and 
recurrent ischemic events in patients with ACS. The association of troponin 
elevation with high-risk coronary lesion morphology provides mechanistic 
insight into studies demonstrating that patients with even minor elevations in 
cTnT or cTnI derive substantial benefit from an aggressive approach with 
respect to GPIIb/IIIa inhibitors, low-molecular-weight heparin and an early 
invasive management strategy.36–38 
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The clinical significance of minor (borderline) elevation in cardiac 
troponins has generated controversy, because most immunoassays have high 
variability near the lower limits of detection. An ACC/European Society of 
Cardiology committee has argued that the diagnostic threshold for MI should 
be set at the lowest level at which the coefficient of variation (CV) is <10 
percent.39 However, several studies show that patients with "borderline" 
troponin values (between the lower limit of detection and the level of 10 
percent CV) have similar ischemic event rates and derive similar benefit from 
aggressive therapy as do patients with more markedly elevated troponin 
values.37, 40 
Plasma levels of BNP and the N-terminal fragment of its prohormone 
(NT pro-BNP) may rise in response to cardiac ischemia in proportion to the 
size and severity of the ischemic insult.41 In patients with UA/NSTEMI, higher 
levels of BNP or NT pro-BNP measured at presentation or during 
hospitalization are associated with a markedly increased risk for subsequent 
death or heart failure, even among patients with normal troponin levels and no 
evidence of heart failure42–44 In a recent substudy of the Aggrastat to Zocor (A 
to Z) trial involving 2901 patients with ACS, those with persistent BNP 
elevation >80 pg/mL at 4 or 12 months after ACS had a three- to fourfold 
increased risk for death at 2 years, compared to patients with persistently low 
BNP levels.45 These findings suggest that serial BNP or NT pro-BNP 
measurements may provide incremental prognostic value in patients following 
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ACS. Despite robust and reproducible prognostic data, the therapeutic 
implications of isolated BNP or NT pro-BNP elevation in patients with 
UA/NSTEMI have not been delineated. Thus, currently, we recommend only 
selective measurement of BNP and NT pro-BNP in patients with ACS. 
Newer Biomarkers 
Myeloperoxidase (MPO) is a neutrophil enzyme that has been 
postulated to play a role in low-density lipoprotein (LDL) oxidation. Among 
604 patients presenting to an emergency room with chest pain, initial plasma 
MPO levels predicted the risk of MI and of major adverse cardiac events at 30 
days and 6 months, even among those with negative cTnT levels.48 The 
prognostic value of MPO appeared to be particularly robust when measured 
early after symptom onset, when troponin elevation may not have yet occurred. 
However, MPO is a nonspecific marker of inflammation and oxidative stress, 
and elevated levels do not alter therapy in ACS at this time. 
The ability of albumin to bind transitional metals such as copper and 
cobalt is altered in the setting of ischemia. The albumin cobalt binding test 
measures ischemia-modified albumin (IMA). In one study of 208 patients 
presenting to the emergency room with chest pain consistent with ACS, 
sensitivity of IMA to diagnose ACS was 82 percent; and the combined 
sensitivity of the ECG, cTnT, and IMA was 95 percent, significantly higher 
than the 53 percent sensitivity of the ECG and cTnT alone.49 A recent meta-
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analysis has validated the high sensitivity and negative predictive value of IMA 
for detecting ACS, especially in combination with troponin and ECG 
measurements;50 specificity, however, is very poor.49 Increased IMA values are 
found with infection, cancer, renal or liver disease, and ischemia in organs 
other than the heart. Thus, most patients with an elevated IMA value will have 
"false-positive" evaluations for ischemia. 
Despite the promise of newer biomarkers for risk stratification in ACS, 
in practice the only markers that should be measured routinely for risk 
stratification are troponin I or T. 
Stress Testing 
Stress testing is often used for risk assessment in patients with 
UA/NSTEMI. Low-risk and some intermediate-risk patients who stabilize with 
medical therapy undergo stress testing for advanced risk stratification. Those 
with high-risk findings, such as large, reversible perfusion defects or ST-
segment depression at low exercise levels, should undergo coronary 
arteriography; those with negative or low-risk results can be treated medically. 
This approach has been validated in patients with UA/NSTEMI, demonstrating 
that high-risk abnormalities correlate with a higher event rate during followup 
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American College of Cardiology/American Heart Association 
Recommendations for Noninvasive Risk Stratification 
High risk (>3% annual mortality rate)  
1. Severe resting LV dysfunction (LVEF <0.35) 
2.  High-risk treadmill (Score > -11) 
3.  Severe exercise LV dysfunction (exercise LVEF <0.35) 
4.  Stress-induced large perfusion defect (particularly if anterior) 
5.  Stress-induced multiple perfusion defects of moderate size 
6.  Large, fixed perfusion defect with LV dilation or increased lung uptake 
7. Stress-induced moderate perfusion defect with LV dilation or increased 
lung uptake (thallium 201) 
8.  Echocardiographic wall motion abnormality (involving more than two 
segments) developing at a low dose of dobutamine (10 mg/kg/min) or at 
a low heart rate (<120 beats/min) 
 9.  Stress echocardiographic evidence of extensive ischemia 
Intermediate risk (1 to 3 % annual mortality rate)  
1.  Mild/moderate resting LV dysfunction (LVEF 0.35–0.49) 
2.  Intermediate-risk treadmill score (score –11 to +5) 
 3.  Stress-induced moderate perfusion defect without LV dilation or 
increased lung intake 
4.  Limited stress echocardiographic ischemia with a wall motion 
abnormality only at higher doses or dobutamine involving 2 segments 
21 
Low risk (<1% annual mortality rate)  
1.  Low-risk treadmill (score > +5) 
2.  Normal or small myocardial perfusion defect at rest or with stress 
3.  Normal stress echocardiographic wall motion or no change of limited 
resting wall motion abnormalities during stress 
Patients who complete a stay in a chest pain unit without objective 
evidence of myocardial ischemia can safely undergo stress testing for diagnosis 
and prognostic purposes either immediately or as an outpatient within the next 
24 to 48 hours. 
In patients who are unable to exercise, pharmacologic testing with 
dipyridamole, adenosine, or dobutamine can be used as the stress and sestamibi 
imaging or echocardiography can be used as a method of assessment. Stress 
testing is not needed in patients whose clinical features already put them at 
high risk; and should proceed directly to coronary arteriography. 
Coronary Angiography 
Risk in coronary patients traditionally has been assessed according to 
the number of vessels with >50 percent diameter stenosis and the presence and 
severity of LV dysfunction. However, the relative prognostic impact is 
probably less with ACS, as the risk of short-term events is dominated by 
features of the culprit lesion, such as whether it induces ST-segment depression 
or troponin release. 
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Among patients with UA/NSTEMI who undergo arteriography, 
approximately 25 percent will have one-vessel disease, 25 percent will have 
two-vessel disease, and 25 percent will have three-vessel disease. Ten percent 
will have significant main stenosis, and the other 15 percent will have coronary 
luminal narrowing of <50 percent or normal vessels on arteriography.51 
Patients with left main stenosis of at least 50 percent, or three-vessel disease 
with LV dysfunction, derive a survival benefit from coronary artery bypass 
surgery. Importantly, patients with no significant lesions at angiography benefit 
from a reorientation of their management. Noncardiac causes of chest pain 
should be considered (including pulmonary embolism), as well as "syndrome 
X" and variant angina. If the coronaries are completely normal, antithrombotic 
and anti platelet drugs can often be discontinued, and the need for anti anginal 
medication reassessed. Patients who are most likely to have no significant 
lesions at angiography tend to be women with no ECG changes. Nevertheless, 
the finding of no significant lesions at angiography is usually unanticipated. 
Importantly, symptomatic patients with "normal" coronary artery contrast 
laminography may have severe coronary atherosclerosis on intravascular 
ultrasound, with coronary artery remodelling  
Risk Models and Risk Scores 
Risk models and scores predict a probability for adverse outcomes based 
on combinations of clinical, ECG, and laboratory data available at presentation. 
The TIMI and PURSUIT scores were derived from clinical trial databases, 
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whereas the GRACE (Global Registry of Acute Coronary Events) score was 
derived from a large international registry.31,52, 53 Although all three methods 
discriminate patients at high versus low risk for short- and intermediate-term 
adverse outcomes, the GRACE model provides better calibration between 
predicted and observed rates of death.54,55 
The TIMI score does not include any measurement of heart failure. The 
GRACE model was developed in a less-selected patient population and 
includes renal insufficiency as a variable, which are two potential advantages 
over the other methods. The major advantage of the TIMI score is that it is a 
simple integer sum that can be calculated at the bedside without a calculator, 
whereas PURSUIT and GRACE use weighted averages of multiple risk factors 
and may require a computer to calculate. None of the models incorporates 
information from newer biomarkers such as troponin, BNP, or CRP. 
Prognosis 
Prognosis in patients with UA or UA/NSTEMI depends on the 
combination of the morbidity or mortality expected from the extent of coronary 
stenosis and LV dysfunction and the short-term risk associated with the culprit 
lesion and the unstable state of ACS. Risk is highest early after the onset of 
symptoms. 
Published reports concerning UA are influenced by patient selection and 
treatment and can be quite misleading. The inclusion and exclusion criteria for 
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clinical trials introduce bias by often eliminating low- or high-risk patients. 
Comparisons of incidence and outcome of UA/NSTEMI since the adoption of 
routine troponin testing are problematic, as the proportion of patients classified 
as NSTEMI has increased and overall mortality risk of NSTEMI may have 
fallen as a consequence.56 
Recent data from the GRACE study show a 6-month mortality rate of 
6.2 percent in patients with NSTEMI and 3.6 percent in those with unstable 
angina. Rehospitalisation rates over the 6 month period were approximately 20 
percent and revascularization rates approximately15 percent.57 
Treatment Overview 
The aims of therapy for UA/NSTEMI patients are to control symptoms 
and prevent further episodes of myocardial ischemia and/or necrosis. Beta 
Blockers, nitrates, and, to a lesser extent, calcium channel blockers reduce the 
risk of recurrent ischemia. Revascularization eliminates ischemia in many 
patients. The risk of MI is diminished by antiplatelet and antithrombotic drugs. 
Aggressive statin therapy plays an increasingly important role following ACS. 
Hospitalized moderate- to high-risk ACS patients should be treated with 
aspirin (ASA), clopidogrel, antithrombin therapy, a beta blocker, statin, and, in 
selected individuals, a GPIIb/IIIa inhibitor. Furthermore, critical decisions are 
required regarding the angiographic strategy. One option, commonly termed 
the early invasive strategy, incorporates an angiographic approach in which 
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coronary angiography and revascularization are performed unless a 
contraindication exists. Previously, the most common approach included an 
initial period of medical stabilization. More recently, many physicians are 
taking an earlier aggressive approach, with coronary angiography and 
revascularization performed within 24 hours of admission when possible. The 
rationale for earlier intervention includes the demonstrated protective effects of 
adjunctive antiplatelet and antithrombin therapy on procedural outcome; recent 
data demonstrating no advantage for the "cooling off" period before 
catheterization58; and the desire to shorten hospital stays as much as possible. 
The alternative approach, the early conservative strategy, is guided by 
myocardial ischemia, with angiography reserved for patients with recurrent 
ischemia at rest or a high-risk noninvasive evaluation for ischemia. This 
strategy is better described as selective invasive as it requires aggressive 
medical intervention and risk stratification. Regardless of the angiographic 
strategy, an assessment of LV function should be strongly considered because 
it is imperative to treat patients who have impaired LV systolic function with 
both angiotensin-converting enzyme (ACE) inhibitors and beta blockers unless 
contraindicated, and when appropriate, coronary artery bypass graft (CABG) 
surgery. When the coronary angiogram is performed, a left ventriculogram 
usually should be obtained at the same time. When coronary angiography is not 
scheduled, the patient is evaluated at rest and/or with stress for inducible 
myocardial ischemia or LV systolic dysfunction. 
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METHODOLOGY 
Patients 
Those patients with Unstable angina Class III B admitted to the 
coronary care unit at the department of cardiology, Madras medical college and 
general hospital, Chennai between Jan 2010 to April 2010 were enrolled in our 
study. Patients treated and stabilised with Heparin, antiplatelets aspirin and 
clopidogrel, statin therapy, betablockers and Angiotensin converting enzyme 
blockers.  
Along with treatment, routine serial investigations of Creatine kinase 
and Creatine kinase MB done at 6, 12, 24hours. Continuous ECG monitoring 
was performed on all patients during their stay in the coronary care unit.  
Those patients with normal cardiac enzymes and those who fulfil our 
inclusion and exclusion criteria are enrolled in our study with proper consent. 
All patients underwent coronary angiography before discharge from the 
coronary care unit. This study was in accordance with the declaration of 
Helsinki. 
Inclusion Criteria 
Criteria for the patients to be included were well defined.   
Those patients with unstable angina of Braunwald Class III B included in our 
study irrespective of sex and age. 
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Exclusion criteria 
1.  Patients with evidence of myocardial infarction on admission with 
corresponding electrocardiographic changes 
2.  Patients with myocardial infarction within 2 months 
3.  Patients admitted with Acute Coronary syndrome with elevated serum  
levels of Lactate dehydrogenase, Creatine kinase, Creatine kinase MB 
4.  Patients with pulmonary edema on admission 
5.  Patients with valvular heart disease 
6.  Patients with evidence of infection 
7.  Patients with malignancies 
8.  Patients with inflammatory of disease of any aetiology tend to elevated 
CRP levels 
C-Reactive protein 
Blood sample of 5ml collected from all those patients included in the 
study after getting consent and then immediately serum separated.  Separated 
serum properly preserved in the prescribed cold conditions in the refrigerator 
and sent for analysis at Thyrocare laboratories on same day and hs-CRP levels 
estimated with nebulometric technique and properly standardized.  
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Coronary angiography 
Using standard techniques, all patients underwent coronary angiography 
within 5 days of admission after getting high-risk consent. The angiogram were 
reviewed independently by two cardiologist blinded to the results of hs-CRP 
levels. Disease vessels were defined by the presence of a lesion with 40% or 
more of diameter stenosis.  Lesions were characterized according to severity of 
diameter stenosis [<50%, 50-70%, >70% and 99%, graded from 1 to 4] and 
morphology according to American heart association/American college of 
cardiology classification [A, B1, B2 or C graded from 1 to 4].  
A complexity score of lesion anatomy was assigned according to the 
sum of the grade of severity of diameter stenosis and morphology of the lesion. 
The culprit lesions in patients were identified as follows: presence of only one 
lesion, correlation with ST-T changes on ECGs during anginal attacks and 
correlation with findings on echocardiograms.  In the remaining patients who 
had only two lesions with equal complexity scores, one of them was arbitrarily 
chosen to be the culprit.  In patients who had two or more different lesions, the 
one with highest complexity score was identified as the culprit. There were 
patients with normal coronary angiogram. 
Complexity of the culprit lesion were graded as low [score less than 4], 
intermediate grade [score 4 & 5] and high grade [6 or more]. 
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Statistical analysis 
Those patients with normal hs-CRP levels with unstable angina[Group 
I] compared with patients with high hs-CRP levels[Group II] in regard to 
complexity of culprit coronary lesion anatomy with Fischer exact test. 
Statistical comparison was two tailed and a p value of less than 0.05 was 
considered statistically significant. Continuous variables analysed with 
unpaired t test and Mean, Standard deviation, Standard error of Mean and 
confidence interval of 95% assessed. 
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RESULTS 
Patients who were admitted and stabilised in CCU and those who 
fulfilled inclusion criteria and after getting proper consent enrolled in the study. 
Total of 92 patients with unstable angina and normal CKMB levels underwent 
coronary angiography after getting proper written consent. The mean time to 
angiography from admission was approximately 4 days. Among 92 patients, 42 
[46%] were with normal hs CRP levels less than 3mgm per litre and 50 [54%] 
were with high hs CRP levels more than 3mgms per litre. The difference in the 
number of subjects is not statistically significant. All the patients underwent 
coronary angiography and procedure was uneventful without any adverse 
effects. 
The mean age of the patients enrolled in Group I with normal hs CRP 
levels was 49.74+/ 10.05 years and in Group II with elevated hs CRP levels 
was 51.32+/8.47 years.  The difference between both groups were not 
statistically significant 
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Table 1 showing Baseline characteristics of Group I with normal hs CRP and  
Group II with elevated hs CRP levels 
CHARACTERS 
GROUP I 
[hs CRP 
levels 
< 3mgms/l] 
GROUP II 
[hs CRP 
levels > 
3mgms/l] 
P 
VALUE 
SIGNIFI-
CANCE 
TOTAL [92] 42 [46%] 50 [54%] 0.3230 NS 
AGE IN YRS 49.74 +/ 
10.05 51.32  +/8.47 0.4147 NS 
MALE            70[76%] 34[37%] 36[39%] 0.3393 NS 
FEMALE       22[24%] 8 [09%] 14 [15%] 0.4628 NS 
FAMILY H/O CAD       
                       28[30%] 
12 [13%] 16 [17%] 0.5020 NS 
SMOKERS    62[67%] 28 [30%] 34 [37%] 1.0 NS 
DIABETES MELLITUS    
                       34[37%] 
16 [17%] 18 [20%] 1.0 NS 
HYPERTENSION 
                      57 [62%] 
24 [26%] 33 [36%] 0.2930 NS 
HYPERLIPIDEMIA  
                       44 [48%] 
18 [20%] 26 [28%] 0.4092 NS 
HISTORY OF CAD 
                       23[25%] 
13 [14%] 10 [11%] 0.1613 NS 
PREVIOUS 
REVASCULARISATION - - - - 
 
 
32 
Fig 1 showing Gender distribution of both Group I and Group II  
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Total number of Males were 70 [76%] and females were 22 [24%].  
Males  in the Group I with normal hs CRP levels were 34 [37%] compared 
with Group II with elevated hs CRP levels of 36 [39%] and found to be 
statistically insignificant [p value =0.3393]. Among 22[24%] females, 8 [09%] 
were in the Group I and 14 [15%] were in Group II and the difference was 
statistically insignificant [P=0.4628]. 
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Fig 2 showing Relative frequencies of risk profile of Group I with normal hs 
CRP levels and Group II with elevated hs CRP levels 
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Among the risk factors, Smoking and Hypertension were the most 
common risk factors present in  62[67%] & 57[62%] respectively. 
Dyslipidemics were 44 [48%] and Diabetics were 34[37%]. Hypertensives 
were 24 [26%] in Group I with normal hs CRP levels and 33 [36%] in the 
elevated hs CRP levels and p value is insignificant [p=0.2930]. Dyslipidemia 
found among 18 [20%] in the Group I and 26 [28%] in the Group II and 
diffference is statistically insignificant [p=0.4092]. Smokers in the Group I 
were 28 [30%] and 34 [37%] in the Group II and p value [>.05] is statistically 
insignificant. In this study, Diabetics were 34 [37%] and out of which 16 [17%] 
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in the Group I and 18[20%] in the Group II and difference between them is 
statistically insignificant [p>0.05]. 
Those with family history of CAD in the study were 28 [30%] and 
among them, 12 [13%] and 16 [17%] were in the Group I with normal hs CRP 
levels and Group II with elevated hs CRP respectively. The difference between 
the two groups is statistically insignificant [p=0.5020].  Those with previous 
history of CAD were 23 [25%] and distributed in the Group I and Group II as 
13 [14%] and 10 [11%] respectively and p value is insignificant [p=0.1613].  
All the baseline characteristics among the both groups were comparable and no 
confounding variable present among them as the values were statistically 
insignificant. 
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Table 2 showing CLINICAL PROFILE OF GROUP I AND GROUP II 
PARAMETER 
GROUP I 
[N=42] 
GROUP II 
[N=50] 
P VALUE SIGNIFIANCE
PULSE RATE 
 
84.19 ± 7.42 88.40 ± 6.7 P=0.0053 S 
SYSTOLIC BP 138.9 ± 11.29 142.2 ± 13.43 P=0.2122 NS 
DIASTOLIC BP 86.24 ± 5.68 87.88 ± 6.67 P=0.2117 NS 
ECG CHANGES [14%] 30 [33%] P=0.0067 S 
LV 
DYSFUNCTION 11[12%] 21 [23%] P=0.1290 NS 
DURATION OF 
 STAY IN CCU 
1.02 ± 0.15 2.08 ± 0.85 P=0.0001 S 
TIMI RISK 
SCORE 2.17 ± 1.08 2.28 ± 0.76 P=0.5182 NS 
 
Clinical profile of Group I with normal hs CRP levels and Group II with 
elevated hs CRP levels were studied. Pulse Rate was 84.19 ± 7.42 in Group I 
and 88.40 ± 6.7 in Group II. The difference between is statistically significant 
[p=.0053].  Systolic BP was 138.9 ± 11.29 in Group I and 142.2 ± 13.43 in 
Group II and P value is statistically not significant [p=0.2122].  Diastolic BP 
was 86.24 ± 5.68 in group I and 87.88 in Group II and p value is statistically 
not significant [0.2117]. Those in the Group I stayed in CCU was 1.02 ± 0.15 
days and Group II stay in CCU was 2.08 ± 0.85 and the difference was highly 
significant. [p=0.0001]. TIMI risk score in the group I was 2.17 ± 1.08 and 
TIMI risk score in the Group II was 2.28 ± 0.76 and there was no statistical 
difference [p=0.5182]. Those with TIMI risk score 3 and above were 14[15%] 
in Group I and 21[23% in Group II. 
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Table 3 showing CORRELATION OF CRP LEVELS AND LV 
FUNCTION OF  GROUP I & GROUP II 
LVF 
NORMAL 
HS CRP 
LEVELS 
HIGH HS 
CRP 
LEVELS 
TOTAL PVALUE 
NORMAL 31 [34%] 29 [32%] [66%]  
MILD 7 [8%] 14 [15%] 21 [23%]  
MODERATE 4 [4%] 6 [7%] 10 [11%]  
SEVERE - 1 [1%] 1 [1%]  
    P=0.1290 
 
There is no statistical difference between Group I and Group II in regard 
to LV dysfunction in those enrolled in the study.  Those with LV dysfunction 
in Group I were 11[12%] in Group I and 21[23%] in Group II and P value is 
0.1290.  Among them, those with normal Lv function were 31[34%] & 
29[32%] in Group I and Group II respectively. Those with mild and moderate 
LV dysfunction in Group I were 7[8%] & 4[4%] respectively.  Those with 
mild, moderate and Severe LV dysfunction in Group II were 21[23%], 
10[11%] & 1 [1%] respectively. 
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Table 4 showing DISTRIBUTION OF CORONARY ARTERY DISEASE IN  
GROUP I & GROUP II 
CAD GROUP I [N=42] 
GROUP II 
[N=50] 
TOTAL 
[92] P VALUE 
NO DISEASE 32 [35%] 5 [05%] 37 [40%] 0.0001[S] 
SINGLE 
VESSEL 4 [04%] 16 [17%] 20 [22%] 0.0112[S] 
DOUBLE 
VESSEL 4 [04%] 17 [18%] 21 [23%] 0.0061[S] 
TRIPLE 
VESSEL 2 [2%] 12 [13%] 14 [15%] 0.0174[S] 
 
Fig 3 showing distribution of coronary artery disease in Group I and Group II 
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Distribution of coronary artery disease among 92 study patients were No 
disease 37[40%], Single vessel disease 20 [22%], Double vessel disease 21 
[23%] and Triple vessel disease 14 [15%]. In regard to No disease 37 [40%], 
Group I with normal hs CRP level were 32 [35%] and study group with 
elevated hs CRP level were 5 [05%] and found to be statistically significant 
[p=0.0001]. Those with Single vessel disease 20 [22%], those with normal hs 
CRP level were 4 [4%] and with elevated hs CRP were 16 [17%] and found to 
be statistically significant.  Those patients with Two vessel disease, of 22 
[23%], control and study group were 4 [04%] and 17 [18%] respectively and 
the difference was statistically significant [p=0.0061].  Patients with Triple 
vessel disease were 14 [15%] and study group with elevated hs CRP were 12 
[13%] compared with control group with normal hs CRP level were 2 [2%] and 
the values were statistically significant [p=0.0174].  
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Those with coronary artery disease in the study were 55 [60%] and out 
of which culprit artery localised to LAD in 30 [32%], 5[5%] in Group I and 25 
[27%] in the Group II. Circumflex involved in 08[09%]of the study population, 
of which those with normal hsCRP levels were 2 [2%] and those with elevated 
hs CRP levels were 6 [7%]. RCA diseased were 17[18%], of which 3 [3%] 
were from Group I and 14 [15%] were from Group II. All the differences 
among both groups for localisation of culprit lesion were statistically 
insignificant. 
Table 5 showing Location of the Culprit Lesion  
CORONARY 
ARTERY 
GROUP I 
[N=42] 
GROUP II 
[N=50] 
TOTAL SIGNIFICANCE
LAD 5 [5%] 25 [27%] 30 1.0 ns 
CIRCUMFLEX 
 
2 [2%] 06 [7%] 08 0.6273 ns 
RCA 
 
3 [3%] 14[15%] 17 1.0 ns 
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Complexity of the culprit lesion were graded according to the score of 
anatomical complexity as low, intermediate and high with scores of less than 3, 
4&5 and 6 or more respectively and compared in both Group I with normal hs 
CRP levels and Group II with elevated hs CRP levels.  Of 55 patients with 
coronary artery disease, low grade were 7[7%] in the Group I and 12[13%] in 
the Group II and the difference is not statistically significant [p=0.4459]. 
Intermediate grade were 2[3%] in the Group I and 22[24%] in the Group II and 
p value is statistically significant [p=0.0001].  High grade complexity were 
1[1%] in the Group I and 11[12%] in the Group II and the difference is 
statistically significant. [p=0.0053].  
Table 6. Correlation of Complexity of Culprit Lesions Between Group I & 
Group II 
COMPLEXITY 
NORMAL 
hs-CRP [42] 
ELEVATED 
hs-CRP [50] 
Total p value 
NORMAL 32[35%] 5[5%] 37[40%] 0.0001[S] 
LOW GRADE 
[SCORE 1,2,3] 
7 [7%] 12 [13%] 19 [20%] 0.4459[NS]
INTERMEDIATE 
[SCORE 4,5] 
02 [03%] 22 [24%] 24 [27%] 0.0001[S] 
HIGH GRADE 
[6 OR MORE] 
01 [1%] 11 [12%] 12 [13%] 0.0053[S] 
ABNORMAL 10[11%] 45[49%] 55[60%] 0.0001[S] 
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The levels of hsCRP among Group II in correlation with severity of 
culprit lesion studied. Those with normal and low grade culprit lesions [n=17], 
Median hs CRP levels were 5.425 with standard deviation of 1.779 and 95% 
confidence interval being 4.477 to 6.373.  Those with intermediate grade 
lesions [n=22], Median hs CRP levels were 6.435 with standard deviation of 
2.086 and 95% confidence interval being 5.53 to 7.33.  Those with high grade 
complex culprit lesions [11], Median hs CRP levels were 8.745 with standard 
deviation of 1.496 and 95% confidence interval was 7.741 to 9.75. 
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Table 7. Correlation of CRP with Severity of Lesions in Group II with Elevated 
CRP Levels 
COMPLEXITY 
 
CRP MEAN S.D CI 95% 
LOW & 
NORMAL 5.425 1.779 4.477 TO 6.373 
MEDIUM 6.435 2.086 5.53 TO 7.33 
HIGH GRADE 
 
8.745 1.496 7.741 TO 9.750 
 
Fig 5 showing correlation of hs CRP levels with various grades of Group II 
patients 
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Clinical outcome of the study population followed upto May 2010 and 
No death reported in the study population.  Those who underwent PTCA with 
Stenting done in total of 9 patients, out of which 1 is from Group I and 8 in 
Group II.  Total 8 patients were stented to LAD and 1 patient with RCA. Those 
who underwent CABG, out of 6 2 were from Group I and 4 in Group II.  
During short period of observation upto May 2010, 13 were readmitted with 
diagnosis of unstable angina 7, Acute LV failure 2 and Myocardial infarction 4. 
In Group I, 2 were admitted with diagnosis of unstable angina & Myocardial 
infarction.  In Group II, Out of 11 patients, 7 were readmitted with unstable 
angina, 2 with Acute LV failure and 3 with Myocardial infarction [P = 0.03 S]. 
Table 8. Correlation of CRP Levels with Clinical Outcome of Patient 
OUTCOME GROUP I GROUP II SIGNIFICANCE 
DEATH NIL NIL - 
PTCA   9[10%] 1[1%] 8[9%] P=0.0347[S] 
CABG  6[6%] 2[2%] 4[4%] P=0.6845[NS] 
READMISSION    
13 [14%] 2[2%] 11[12%] P=0.0324[S] 
UA       7[7%] 1 [1%] 6[6%]  
LV FAILURE  
2[2%] NIL 2[2%]  
MYOCARDIAL 
INFARCTION4[4%] 1[1%] 3[3%]  
 
 
44 
 
 
 
Figure 6 Showing High Grade Complex Lesion of Mid RCA Lesion 
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Figure 7 Showing Mid LAD Complex Culprit Lesion 
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Figure 8 Showing PTCA With Stenting Done To Mid Lad Lesion 
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Figure 9 Showing High Grade Culprit Lesion Of Proximal LAD 
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Figure 10 Showing Post PTCA with Stenting to Proximal LAD 
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DISCUSSION 
 The contribution of inflammation to the pathogenesis of the 
syndrome of unstable angina is emerging as a profoundly relevant factor.  
Recent molecular biological studies have elucidated the relation between 
cytokines evoked by activated macrophages and plaque vulnerability.  
Inflammation causes imbalance between fibrous cap degradation and repair. 
Several clinical observations have established a quantitative relationship 
between the degree and level of inflammation and the clinical outcome in 
symptomatic and asymptomatic patients with coronary artery disease. 
However, data correlating the markers of inflammation with angiographic 
anatomy are scarce.  This study confirms previous observations relating 
inflammation and need for revascularisation.  It also provides new knowledge 
pertaining to the link between inflammation and coronary events. We noted 
significant correlation between elevated CRP levels and the grade of culprit 
lesions anatomical complexity in patients with unstable angina.  Thus, a strong 
interaction between plaque inflammation and thrombosis seems to be the basis 
of unfavourable plaque transformation, anatomical complexity and consequent 
adverse clinical event. 
 In this study, Total 92 patients who were included, Baseline 
characteristics compared between 42 [46%] of Group I with normal hs CRP 
levels and 50 [54%] of Group II with elevated hs CRP patients.  There was no 
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statistical difference between the two groups and thereby both groups 
compared without confounding variables. Mourkabel et al.59 studied CRP level 
with complexity of coronary lesions in Unstable angina included 96 patients 
with 19 patients were with normal CRP levels and 77 patients were with raised 
CRP levels. Ghazala irfan et al60 included 34% of unstable angina patients out 
of 100 patients in the study of hs CRP and angiographic characteristic of 
coronary lesions. Ghazala irfan et al included 9 patients with normal hs CRP 
levels and compared 25 patients with elevated hs CRP levels and also study  
population included NSTEMI & STEMI. Comparing our study with Mourkabel 
et al59 and Ghazala irfan et al.,60 Group I with normal hs CRP were not only 
higher in number and also there was no statistical significance between both 
study and control groups [p=0.3230] and thereby correlation with hs CRP 
levels with severity of lesions and identification of complex culprit lesion 
anatomy was true reflection of significance than Mourkabel et al and  
Ghazala et al. 
 In our study, out of total 22 [24%] females, there was no statistical 
significant difference [p=0.4628] between 14 [15%] patients of Group II with 
elevated hs CRP levels and 08 [09%] patients of Group I with normal hs CRP 
levels. Ghazala irfan et al included 36% females in the study group and 
Mourkabel et al included 26% females in the study sample. Study by Ridker et 
al61 in regard to “ C reactive protein and other markers of inflammation in the 
prediction of cardiovascular disease in women” and concluded that hs CRP 
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emerged as the strongest univariate predictor of the risk of cardiovascular 
events and recommended hs CRP in addition to lipid profile to identify women 
at risk for cardiovascular events. 
 In this study, Hypertension, Hyperlipidemia, Smoking and Diabetes are 
the major risk factors with representation of 62%, 48%, 67% and 37% 
respectively among study population. Mourkabel et al study population 
comprised 24% hypertensive, 57% Hyperlipidemia, 62% smokers and 19% 
diabetics. Ghazala irfan et al included 55% diabetics, 66% hypertensive, 
smokers 36%. In TIMI 11A sub study29, study population [630] included 
diabetics 37%, smokers 26% and hypertensive 62%. Among 57[62%] 
hypertensive in this study, 24[26%] in the Group I and 33[36%] in the Group II 
with equal distribution and the difference was not statistically significant 
[p=0.2930]. Diabetics were 16[17%] in the Group I and 18[20%] in the Group 
II and the difference was not statistically significant. Dyslipidemia was seen 
18[20%] in the Group I with normal hs CRP levels  and 26[28%] in the Group 
II with elevated hs CRP levels and there was no statistical significance between 
them [p=0.4092]. Smokers were 28 [30%] in the Group I and 34[37%] in the 
Group II and there was no statistical difference between two groups [p=1.0]. 
There was no statistical difference between Group I with normal hs CRP levels  
and Group II with elevated hs CRP levels in regard to  risk factors in our study 
and thereby doesn’t influence the end result between both groups. 
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 In our study, 23[25%] with previous history of coronary artery disease 
with distribution of 13[14%] in the Group I with normal hs CRP levels and 
10[11%] in the Group II with elevated hs CRP levels and there was no 
statistical difference between both groups [p=0.8336]. Mourkabel et al59 study 
population included 38% with previous history of CAD and Ghazala et al60 
included 43% with previous CAD.   There were no patients in this study with 
previous history of CABG and PCI but study population in Mourkabel et al. 
and Ghazala et al. were 16 [16.7%] and 27 [27%]. In TIMI 11 A study29, 
Previous history of CAD included 57% with diameter stenosis of coronary 
arteries more than 50% and also included PTCA 15%, CABG 12% and 
Previous MI 2.5% 
 In this study 28[30%] were with family history of Coronary artery 
disease distributed as 12[12%] in the Group I and 16[17%] in the Group II with 
no statistical significance [p=0.5020]. Mourkabel et al included study 
population of 56[58.3%] with family history of Coronary artery disease.  
 In our study, Mean age of the patients in Group I with normal hs CRP 
levels were 49.74 ± 10.07 and in Group II with elevated hs CRP levels were 
51.32 ± 8.42.  The difference between both groups were not statistically 
significant.  The mean age of patients in Mourkabel et al was 57 ± 10 years. 
The mean age in Ghazala et al. was 59.26 ± 11.04 years. Gusto risk score has 
given score of 2 for the patients with age in between 50-59 years and this itself 
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indicates 30 day mortality risk of 0.4% and any other added risk factor may 
increase 30 day mortality rate significantly. 
 Clinical profile of the patients in Group I and Group II were studied.  
Mean pulse rate in Group I was 84.19 ± 7.42 compared with 88.40 ± 6.7 in 
group II and the difference was statistically significant. This again reconfirms 
the fact that tachycardia in unstable angina patients was one of the risk factor 
for the need for early invasive strategy and HR more than 90 included in the 
risk stratification of Unstable angina patients in Gusto Risk scoring system. 
 Mean Systolic blood pressure in Group I was 138.9 ± 11.29 and in 
Group II was 142.2 ± 13.43 and the Mean diastolic pressure in Group I was 
86.24 ± 5.6 and in Group II was 87.88 ± 6.67 and the difference were not 
statistically significant in regard to blood pressure [p=0.05]. 
 ECG changes of ST depression or T inversion were found among 
43[47%] of study population.  There were 13[14%] in the Group I with ECG 
changes and 30[33%] in the Group II with ECG changes and the difference 
were statistically significant [p=0.0067]. This signifies the importance of ECG 
changes with Unstable angina of high risk category who need early invasive 
strategy in lieu with TIMI risk scoring System. Analysis of 1473 UA or 
NSTEMI patients in the TIMI III trial revealed revealed 90% ECG changes 
includes 10% ST elevation, 33% ST depression and 46% T inversion. Our 
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study revealed 47% ECG changes with ST depression or Symmetrical T 
inversion. 
 Mean TIMI risk score in Group I was 2.17 ± 1.08 in Group I and 2.28 ± 
0.76 in Group II and the difference was not statistically significant [p=0.5182].  
Those with TIMI risk score 3 or more  in Group I were 14 (15%) and 21 (23%) 
and the difference was not statistically significant underlies the significance of 
this study.  The infliction point of high risk of death in TIMI risk stratification 
scoring method is 3 or more and the incidence of death, new or recurrent MI, 
recurrent ischemia requiring revascularisation were 13.2% and more if score is 
3 or more. 
 In our study, There was no statistical difference between Group I and 
Group II in regard to LV dysfunction for those enrolled in the study.  Those 
with LV dysfunction in Group I were 11[12%] in Group I and 21[23%] in 
Group II and P value is 0.1290.  Among them, those with normal Lv function 
were 31[34%] & 29[32%] in Group I and Group II respectively. Those with 
mild and moderate LV dysfunction in Group I were 7[8%] & 4[4%] 
respectively.  Those with mild, moderate and Severe LV dysfunction in Group 
II were 21[23%], 10[11%] & 1 [1%] respectively.  The study population with 
previous history of CAD were only 23[25%] and thereby influenced statistical 
power of this variable in this study and need to be studied with more number of 
patients. 
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 The stay at coronary care unit in Group I was 1.02 ± 0.15 and in Group 
II was 2.08 ± 0.85 and the difference between the groups were statistically 
significant.  This emphasises that those in Group II with elevated hsCRP were 
of high risk category and  needed more duration for stabilisation. 
 In regard to distribution of coronary artery disease, Normal coronaries, 
Single, double and triple vessel diseases were 37[40%], 20[22%], 21[23%] and 
14[15%] respectively. Out of total with no disease 37 [40%], Group I with 
normal hs CRP level were 32 [35%] and Group II with elevated hs CRP level 
were 5 [05%] and found to be statistically significant [p=0.0001]. Those with 
Single vessel disease of 20 [22%], group I with normal hs CRP level were 4 
[4%] and group II with elevated hs CRP were 16 [17%] and found to be 
statistically significant[p=0.0112].  Those patients with Two-vessel disease of 
22 [23%], Group I and Group II were 4 [04%] and 17 [18%] respectively and 
the difference was statistically significant [p=0.0061]. Total patients with 
Triple vessel disease were 14 [15%], study group with elevated hs CRP were 
12 [13%] compared with Group I with normal hs CRP level were 2 [2%] and 
the values were statistically significant [p=0.0174]. Comparing study group 
with Group I, the difference was statistically significant in all categories and 
reflects usefulness of hs CRP in all categories of patients for identifying high 
grade complex lesions in unstable angina. 
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 Mourkabel et al included 25[26%] normal coronaries, 27[28.1%] single 
vessel disease and 23[24%] double vessel disease and 21[21.9%] triple vessel 
disease and the difference was statistically significant in the all categories as in 
our study. 
 In our study, culprit artery localised to LAD were 30%, LCx were 8% 
and RCA 17% compared to Mourkabel et al study population of 43.8% LAD, 
15.6% LCX and 14.6% RCA. Those with coronary artery disease in this study 
were 55 [60%] and out of which culprit artery localised to LAD were in 30 
[32%]-5[5%] in Group I and 25 [27%]in the Group II. Circumflex involved in 
08[09%] of the study population, of which those with normal hsCRP levels 
were 2 [2%] and those with elevated hs CRP levels were 6 [7%]. RCA diseased 
were 17[18%], of which 3 [3%] were from Group I and 14 [15%] were from 
Group II. All the differences between Group I and Group II for localisation of 
culprit lesion were statistically insignificant. There was no confounding bias in 
regard to culprit artery for identification of high grade lesions and doesn’t 
influence the end result of this study. 
 In this study, low grade, intermediate and high-grade complexities of 
culprit lesion anatomy were 20%, 27%and 13% respectively. Of 55 patients 
with coronary artery disease, low grade were 7[7%] in the Group I and 
12[13%] in the Group II and the difference was not statistically significant 
[p=0.4459]. Intermediate grade were 2[3%] in the Group I and 22[24%] in the 
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Group II and p value is statistically significant [p=0.0001].  High-grade 
complexity was 1[1%] in the Group I and 11[12%] in the Group II and the 
difference is statistically significant. [P=0.0053]. 
 While analysing Group II in regard to hs CRP levels and complexity of 
culprit artery lesions, those with normal and low grade culprit lesions [n=17], 
Median hs CRP levels were 5.425 with standard deviation of 1.779 and 95% 
confidence interval being 4.477 to 6.373.  Those with intermediate grade 
lesions [n=22], Median hs CRP levels were 6.435 with standard deviation of 
2.086 and 95% confidence interval being 5.53 to 7.33.  Those with high grade 
complex culprit lesions [11], Median hs CRP levels were 8.745 with standard 
deviation of 1.496 and 95% confidence interval was 7.741 to 9.75. This 
observation in our study reaffirms that increasing hsCRP levels in patients with 
unstable angina identifies complex high grade culprit artery lesions. 
 While comparing the results between normal hs CRP levels and elevated 
hs CRP levels, highest statistical significance found between both groups in 
those with normal coronaries.  There was no statistical significance between 
group I and group II in regard to low-grade culprit lesion but there was 
statistical significance between group I and group II in respect to intermediate 
grade and high-grade complex lesions. In our study, the significance between 
group I study and group II was not there after excluding normal coronaries.  
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 In study of Mourkabel et al compared 19 with normal CRP and 77 with 
elevated CRP levels, there was statistical significance between both groups 
while comparing normal, low, intermediate and high grade lesions even after 
exclusion of normal coronaries. There was a trend toward a higher grade of 
anatomical complexity of culprit lesion in patients with elevated CRP levels 
[p=0.007]. The percent of patients with elevated CRP in Mourkabel et al were 
56% in the low complexity lesions, 84% in the intermediate group and 93% in 
the high complex lesions and the investigators concluded that high CRP levels 
at admission are a marker for anatomical complex lesions. 
 Another study done by Espligureal R et al62 showed that, hs-CRP was 
significantly higher in patients with acute coronary syndrome compared to 
chronic stable angina [P=0.004] and correlate with complex angiographic 
lesion [p=0.001]. 
 Ghazala et al showed that highest CRP levels more than 4mgm/l 
associated with long lesions, irregular lesions and macroscopic thrombus. Thus 
inflammation can be implicated in transformation of stable coronary plaque to 
unstable plaque rupture and Thrombus.  Identification of markers indicating 
propensity of plaque rupture is of  clinical importance and hs CRP may be 
simple and useful in this regard. 
 Study by JA Ambrose et al 1“Angiographic morphology and the 
pathogenesis of unstable angina pectoris” showed that out of 110 patients, type 
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II eccentric lesions with irregular border or narrow neck were found among 63 
patients with unstable angina compared to stable angina patients and found to 
be high statistical significance and represents ruptured atherosclerotic plaques 
or partially occlusive thrombi or both.  
 Liuzzo et al14 showed that in a subgroup of 31 patients with severe 
unstable angina and no evidence of myocardial necrosis by admission 
quantitative cTnT, a serum CRP concentration 0.3mgm/dl [90th percentile of 
normal distribution] was predictive of more frequent recurrent angina and 
exhibited associated trends toward higher rates of revascularisation, MI and 
death. Subsequently, the European concerted action on Thrombosis and 
Disabilities Study group reported a correlation between elevated CRP and non 
fatal MI or sudden cardiac death in 2000 outpatients with stable and unstable 
angina followed prospectively for an average of 2 years, with an odds ratio for 
these events of 1.81 for patients in the highest quartile of CRP relative to those 
in the first to fourth quartiles. 
 In TIMI 11A sub study, C reactive protein is a potent predictor of 
mortality  independently of and in combination with Cardiac troponin in acute 
coronary  syndrome strongly suggests a prognostic role for CRP with respect to 
short-term  mortality. In addition, the present report demonstrates the combined 
prognostic value  of an assay for cTnT and CRP in stratifying patients for 
mortality risk. Notably, among patients with a negative rapid bedside cTnT 
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assay, a markedly  elevated CRP identifies patients who remain at significantly 
increased risk for death  in the first 14 days and thus confers additional 
prognostic information above cTnT  results alone. Furthermore, we observed 
that using the rapid cTnT assay and CRP in  combination provided a more 
comprehensive risk assessment with respect to mortality. Patients with unstable 
angina and NQMI compose a diverse population with  a broad range of risk for 
adverse clinical outcomes (29,30). Thus, the ability to  effectively risk stratify 
patients at presentation should prove useful in triaging patients to the 
appropriate level of hospital care as well as potentially guiding clinical  
interventions. 
 Katiris et al63 assessed the association of preprocedural CRP 
concentrations with clinical presentation (unstable angina) and angiographic 
features of coronary lesions and concluded that among patients with suspected 
CAD undergoing coronary angiography, increased CRP is strongly associated 
with unstable angina and with specific high-risk features of the culprit coronary 
lesions.  
 Study by Zairis et al64, C reactive protein and multiple complex 
coronary artery plaques in patients with primary unstable angina included 228 
consecutive patients with PUA who underwent in-hospital catheterization were 
evaluated. In particular there was a significant gradual increase in either the 
number of Culprit Lesions, or the presence of apparently thrombus-containing 
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Culprit Lesions with increasing of CRP tertiles. By multivariate analysis CRP 
was independently associated with the presence of either multiple Culprit 
lesions (R.R.=1.8, 95%CI=1.5-2.2, P<0.001), or angiographically apparent 
thrombus-containing Culprit lesions (R.R.=1.4, 95%CI=1.2-1.7, P=0.03). High 
plasma levels of CRP may reflect a multifocal activation of the coronary tree in 
patients with unstable angina. This finding suggests a generalized inflammatory 
reaction throughout the coronary tree in these patients. 
 In an unpublished study by panja, mitra et al65 from IPGMER, Calcutta- 
Relationship of hs CRP and angiographic characteristics of coronary lesions: 
An experience in Indian context concluded that hs CRP independently 
predicted high risk coronary artery lesions [Odds Ratio 2.6 per 9 fold increase 
in hs CRP 95% Confidence interval 0.9-3.2: p=0.034] and also identified 62 
culprit lesions with macroscopic thrombus or eccentric/irregular discrete 
morphology without total occlusion. Study population included 100 patients 
with Male 72 and Female 28 in between Jan 2004-June 2004. 
 Clinical outcome of the study population followed upto May 2010 and 
No death reported in the study population.  Those who underwent PTCA with 
Stenting done in total of 9 [10%] patients, out of which 1 [1%] is from Group I 
and 8 [9%] in Group II.  Total 8 [9%] patients, 7 [8%] were stented to LAD 
and 1[1%] patient with RCA. Those who underwent CABG out of 6, 2 [2%] 
were from Group I and 4 [4%] in Group II.  During short period of observation 
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upto May 2010, 13 [14%] were readmitted with diagnosis of Unstable angina 7, 
Acute LV failure 2 and Myocardial infarction 4. In Group I, 2 were admitted 
with diagnosis of unstable angina & Myocardial infarction.  In Group II, Out of 
11 patients, 7 were readmitted with Unstable angina, 2 with Acute LV failure 
and 3 with Myocardial infarction. 
 This study indicates that with short period of stay, Total 13 patients 
were readmitted with diagnosis of Unstable angina, Acute LV failure and 
Myocardial infarction and identified high risk category among those with 
elevated hs CRP levels. The need for earlier revascularisation is high among 
those with elevated hs CRP levels and establishes the level of hs CRP is one of 
the important tools in risk stratification of Unstable angina and identification of 
complex culprit lesion anatomy.  Those patients with high grade and 
intermediate grade complex culprit lesion anatomy were with higher levels of 
CRP and identifies those who need early invasive strategy to decrease future 
cardiovascular events. 
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CONCLUSIONS 
Following conclusions were made out after observation of results of 92 
patients who were admitted with Unstable angina and grouped according to hs 
CRP levels: 
1. Those with elevated hsCRP levels with more than 3mgms per 
litre associated with high Grade complex culprit lesion and in 
turn identified the need for early revascularisation. 
2. Clinical parameters of tachycardia, ECG changes and prolonged 
stay at coronary care unit identifies high risk category among 
study population compared to TIMI risk score, Prior LV 
dysfunction, Hypertension. 
3. Those with hs CRP levels more than 5.53mgms per litre and 
Those with hs CRP levels more than 7.741mgms per litre were 
associated with intermediate and high grade complex culprit 
lesion in those with elevated hsCRP more than 3mgm per litre 
4. Those with elevated hs CRP more than 3mgms per litre were 
associated with increased incidence of readmission, unstable 
angina, Acute Lv failure and Myocardial infarction. 
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LIMITATIONS 
Angiography offers only visual information and has limitations.  For 
example, we could only assess the presence of macroscopic thrombi, whereas 
microscopic thrombi are not uncommon.  Vulnerability of plaques to rupture is 
related to microscopic characteristic of coronary plaques, such as increased 
macrophages, reduced smooth muscle cells, a large soft lipid core and thin 
plaque cap.  Therefore some non-critical appearing lesions may be at high risk 
for rupture.  This would mean that true relationship between lesion morphology 
and CRP is probably even stronger than we observed using only coronary 
angiography. 
In this study, there were no study population with prior history of 
revascularisation. In future, Population with prior history of revascularisation 
will be growing and the necessity to study those population is the need of the 
time as their main clinical presentation will be Unstable angina. The role of hs 
CRP is definitely high and ideal marker for need to redo revascularisation.  
False positive hs CRP and normal coronaries eventhough very low in 
this study but with the back ground of Diabetes being one of the most common 
risk factor among unstable angina patients, Occult infection always may raise 
hs CRP and the more ideal methodologies to be evaluated to rule of infection. 
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Our study population received statins before and after enrolment, the 
influence statins on hs CRP levels is well known fact and it definitely reduces 
hs CRP levels.  This need to be considered in borderline patients. 
Statistical power should be high to conclude association of hs CRP 
levels with complexity of Culprit artery lesions, TIMI risk scoring, prior LV 
dysfunction and clinical outcome of the patients. 
To assess the natural history of impact of high grade complex culprit 
artery lesions in correlation with clinical outcome, follow up in this study was 
short and larger follow will definitely identifies absolute risk associated with 
high complex lesions. 
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ABBREVIATIONS 
ACC   – American college of  Cardiology 
ACE BLOCKERS – Angiotensin converting enzyme 
ACS   –  Acute coronary syndrome 
AHA    – American Heart Association 
BNP   – Brain natriuretic peptide 
CABG  – Coronary Artery bypass Graft 
CAD   – Coronary artery disease 
CAG   – Coronary angiogram 
CKMB   –  Creatinine kinase MB iso enzyme 
CMV   – Cytomegalovirus 
CRP   – C reactive protein 
DVD   – Double vessel disease 
EF   – Ejection Fraction 
GP II b/III a  – Glycoprotein II b - IIIa 
hs CRP  –  high sensitive C reactive protein 
LAD    –  Left anterior Descending Artery  
LCX   – Left circumflex Artery 
76 
LV   – Left ventricle 
MI    – Myocardial infarction 
MPO   – Myeloperoxidase inhibitors 
NSTEMI   –  Non ST elevation myocardial infarction 
PTCA   – Percutaneous Transluminal Coronary Angioplasty 
RCA   –  Right coronary Artery 
S.D   – Standard Deviation 
S.E.M   – Standard error of mean 
STEMI   –  ST elevation myocardial infarction 
SVD   – Single vessel disease 
TIMI   – Thrombolysis in Myocardial Infarction 
TVD   – Triple vessel disease 
UA    – Unstable Angina 
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NAME                                              AGE                                              SEX     
 
ADDRESS  
 
 
 
HYPERTENSION 
 
DM 
 
DYSLIPIDEMIA 
 
TOBACCO USE 
 
ALCOHOL 
 
FAMILY H/O CAD                                                    SCD 
 
 
PREVIOUS CAD 
   
CSA  
 
UA 
 
NSTEMI 
 
STEMI 
 
 
PREV PTCA/CABG 
 
 
PRIOR LV DYSUNCTION   
 
H/O         PVD                                        CVA                                               CKD 
 
 
RA/ COLLAGEN DISORDERS 
ACUTE FEBRILE ILLNESS,  
MALIGNANCY  
CHRONIC INFLAMMATORY DISORDER 
MEDICAL TREATMENT 
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PREV 
 
PRESENT 
 
 
 
CLINICAL  
BRAUNWALD CLASSIFICATION 
 
 
 
 
HAEMODYNAMICS STATUS 
 
PULSE                                  S3 
 
BP                                                 RALES 
 
JVP 
 
LV FUNCTION 
  
ADMN 
 
 BEFORE CAG  
 
ECG  
 
ADMN  
 
BEFORE CAG 
 
DURING CAG 
 
TIMI RISK SCORE 
 
 
 
GUSTO RISK SCORE 
 
 
 
 
BASELINE INV 
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CBC 
 
RFT 
 
CK 
 
CKMB  
6                                     12                                             24 
 
HS CRP 
 
 
TMT 
 
 
 
CAG 
NO                        DATE                                      DONE ON 
 
  
 
LMCA 
 
 
 
LAD 
 
 
 
 
 
 
RI 
 
 
 
LCX 
 
 
 
 
 
 
80 
RCA 
 
 
 
 
 
 
 
 
SCORE 
 
 
 
 
 
 
 
PTCA 
 
 
 
CABG 
 
 
 
MEDICAL 
 
 
 
DEATH 
 
 
 
READMISSION 
 
 
 
UA 
 
LVF 
 
 
INFARCT  
MASTER CHART – I 
 
NAME AGE SEX DIAGNOSIS HTN DIAB 
SMOKE
RS
DYSLI 
PIDEMIA
FAMILY 
H/O PR SBP DBP ECG 
SCO
RE
LV 
FUNCTION TIMI HS CRP
GRO
UP
CCU 
STAY
RAGUPATHY 52 M UA YES NO NO NO NO 94 140 90 
AW 
ISCHEMIA 8 N 2 10.3 2* 2 
ANISHKUMAR 32 M " YES NO YES NO NO 96 160 98 
AW 
ISCHEMIA 6 N 2 10.3 2* 2 
CHINNASAMY 55 M " YES NO YES NO YES 78 130 80 IW ISCHEMIA 3 N 2 0.4 1 1 
 MOHAN 52 M " YES YES NO YES YES 98 140 90 N N N 2 10.3 2* 3 
KUMARI 55 F " YES YES NO NO NO 88 140 84 N N N 1 1.2 1 1 
JOSEPH 74 M " NO NO YES YES NO 98 160 80 
AW 
ISCHEMIA 3 MILD 3 5.4 2* 2 
ANTHONY 48 M 
old 
AWMI NO NO YES NO YES 92 130 80 N 4 MILD 1 6.2 2* 3 
PANDIAN 60 M UA NO YES YES YES NO 86 140 92 N 7 N 2 6.4 2* 3 
HARISHKUMAR 32 M " YES NO NO NO NO 98 132 84 N 0 N 1 0.8 1 1 
CHINNASAMY 55 M " NO YES YES YES YES 94 140 80 N 3 N 2 2 1 1 
SALEEMA BEE 40 F " YES YES NO YES YES 96 146 92 N 5 N 2 6.4 2* 1 
TAMILARASAN 53 M " NO YES YES YES NO 78 140 90 N 3 N 2 4.8 2* 2 
ABDUL RAZAQ 58 M " YES NO YES YES NO 92 156 98 IW ISCHEMIA 4 N 3 8 2* 3 
VEERANAM 43 M " YES YES YES YES YES 78 140 90 N 4 N 2 1.8 1 1 
PALANI 65 M " NO NO YES YES NO 78 140 80 N 0 N 2 0.8 1 1 
SAMUEL 35 M 
old 
AWMI NO NO YES NO NO 84 136 84 
AW 
ISCHEMIA 4 MODERATE 3 8.2 2* 2 
JEYACHANDRAN 50 M 
OLD 
IWMI NO YES YES YES NO 80 120 80 IW ISCHEMIA n MILD 4 2 1 1 
MARIMUTHU 49 M 
OLD 
IWMI NO NO YES NO YES 86 128 80 
AW 
ISCHEMIA 4 MODERATE 3 8.2 2* 3 
LAKSHMANAN 55 M 
old 
AWMI YES NO YES NO NO 98 140 90 
AW 
ISCHEMIA 7 MODERATE 3 10.3 2* 3 
DAULATH BASHA 55 M UA YES NO YES NO NO 96 142 92 N 3 N 1 7.5 2* 1 
RAVO 41 M 
OLD 
IWMI YES NO YES NO YES 82 146 92 IW ISCHEMIA 0 MILD 4 0.4 1 1 
INDIRANI 52 F UA YES NO NO NO NO 92 140 90 
AW 
ISCHEMIA 7 MILD 3 6.4 2* 1 
SARASWATHY 60 F 
OLD 
IWMI NO NO NO NO NO 82 150 80 
AW 
ISCHEMIA 5 MODERATE 3 5.2 2* 2 
HARIDOSS 50 M UA YES YES YES YES NO 96 140 90 N 5 N 2 6.2 2* 2 
BABUKANNAN 38 M " YES YES YES YES YES 78 140 90 N 0 N 1 0.6 1 1 
EDWARD JOSUA 35 M " NO NO YES NO YES 92 120 80 IW ISCHEMIA 0 N 2 5.6 2* 2 
BABYAMMAL 52 F 
OLD 
IWMI YES NO NO NO NO 88 146 92 
AW 
ISCHEMIA 0 MILD 3 1.2 1 1 
MOHD IBRAHIM 57 M UA YES YES YES YES NO 96 132 90 
AW 
ISCHEMIA 7 N 3 10.3 2* 3 
ALPHONSE 57 M " NO NO YES NO NO 80 140 80 N 0 N 2 2.6 1 1 
ABDUL KHALID 76 M " NO YES YES YES NO 88 160 80 
AW 
ISCHEMIA 5 N 4 7.4 2* 2 
vasudevan 49 M " NO NO NO NO YES 76 120 80 N 0 N 1 0.7 1 1 
SARASWATHY 72 F " YES NO NO YES NO 92 160 100 
AW 
ISCHEMIA 6 MILD 3 8.4 2* 2 
RAMASAMY 50 M " YES NO YES NO YES 94 150 90 
IW 
ISCHEMI9A 3 N 3 3.4 2* 1 
RATHINAM 51 F " YES NO NO YES YES 88 140 90 N 5 N 2 8.4 2* 2 
RUKMANI 60 F " NO YES NO YES NO 84 160 80 
AWISCHEMI
A 3 N 2 4.8 2* 1 
GANDHI 47 F " YES YES NO YES YES 80 130 80 N 0 N 2 0.8 1 1 
KANNAIYAN 52 M 
OLD 
AWMI YES NO YES NO NO 78 148 96 
AW 
ISCHEMIA 3 SEVERE 3 3.8 2* 1 
GOVINDAN 60 M UA YES YES YES YES NO 98 180 100 N 7 N 2 8.6 2* 3 
HANIFA 53 M 
OLD 
IWMI NO NO YES YES NO 88 110 70 
AW 
ISCHEMIA 7 MODERATE 3 7.8 2* 2 
AYESHA 48 F UA NO NO NO YES YES 94 120 80 N 0 N 1 0.8 1 1 
RAJA 52 M " YES YES YES YES NO 74 132 84 N 0 N 2 0.6 1 1 
SUBRAMANI 36 M " NO NO YES NO YES 88 120 80 N 0 N 1 6.2 2* 3 
MALLIGA 65 F " YES YES NO YES NO 84 160 90 IW ISCHEMIA 7 MILD 5 2.8 1 1 
SIVABALAN 32 M 
old 
AWMI NO NO YES NO NO 78 120 80 
AW 
ISCHEMIA 2 MODERATE 3 1.5 1 1 
MAHENDRAN 36 M 
OLD 
IWMI YES NO YES NO YES 80 124 82 N 0 MODERATE 3 0.5 1 1 
SUBRAMANI 52 M UA YES NO YES NO NO 90 160 90 N 5 N 1 4 2* 1 
MUNIAPPAN 37 M " YES NO YES NO NO 84 120 80 
AW 
ISCHEMIA 7 N 2 9.6 2* 3 
MAHENDRAN 46 M " NO YES NO YES YES 82 130 80 N 5 N 2 4.6 2* 1 
CHANDRASEKAR 46 M " YES YES YES YES NO 78 160 90 N 0 N 2 1 1 1 
ANBU 35 M 
old 
AWMI NO NO YES NO NO 76 130 84 N 0 MILD 2 2.3 1 1 
SHEELA 45 F UA YES NO NO NO YES 88 138 88 N 6 N 1 7.8 2* 3 
ELANGOVAN 49 M " NO NO YES YES YES 82 126 82 N 0 N 1 0.7 1 1 
SELVAM 40 M " NO YES YES YES NO 94 132 80 N 5 N 2 6.3 2* 3 
VASANTHA 49 F 
OLD 
AWMI NO NO NO YES YES 78 130 80 AW ICHEMIA 3 MODERATE 3 1.3 1 1 
SHANKAR 39 M " YES NO YES NO YES 82 140 90 N 0 N 2 0.6 1 1 
ANANDI 40 F " NO NO NO YES NO 86 140 86 IW ISCHEMIA 5 N 2 3.8 2* 1 
ANGAMMAL 60 F " YES NO NO YES NO 92 160 98 
AW 
ISCHEMIA 8 MILD 2 10 2* 3 
BABU 34 M " YES NO YES NO NO 80 146 92 N 0 N 1 1 1 1 
VASUDEVAN 54 M " NO NO YES NO NO 98 138 80 N 6 N 1 5.7 2* 2 
RAMASAMY 64 M " YES YES YES YES NO 98 156 90 
AW 
ISCHEMIA 6 MILD 3 8.3 2* 3 
PILLAIYAPPAN 51 M " YES YES YES YES NO 88 142 92 N 0 N 2 2.5 1 2 
MASTHAN 71 M " NO NO NO NO NO 84 160 80 
AW 
ISHCEMIA 4 N 3 2.6 1 1 
ALAGUDURAI 57 M " NO NO NO NO YES 82 140 86 N 0 N 1 0.4 1 1 
ARUMUGAM 40 M 
OLD 
IWMI YES YES NO YES YES 88 148 92 N 5 MILD 3 4.8 2* 1 
KUMARI 35 M " YES NO YES NO YES 86 140 90 IW ISCHEMIA 0 N 3 3.7 2* 1 
DOSS 40 M 
OLD 
IWMI YES YES YES NO NO 74 140 90 N 0 N 3 1.3 1 1 
SULTAN 63 M UA NO NO YES NO NO 76 156 78 N 0 N 1 1.3 1 1 
PUSHPA 56 F 
OLD 
AWMI YES YES NO YES NO 78 140 90 AW ICHEMIA 3 MILD 4 3.9 2* 1 
BABU 58 M 
OLD 
AWMI YES NO YES NO NO 84 140 90 N 0 MILD 3 0.6 1 1 
SUBRAMANI 41 M UA NO NO YES YES NO 78 130 80 N 0 N 1 1.7 1 1 
RAMAR 53 M " YES YES YES YES NO 84 142 90 IW ISHCEMIA 0 N 3 2.3 1 1 
GOVARDHAN 48 M " YES NO YES NO YES 86 160 90 
AW 
ISCHEMIA 5 N 3 6 2* 2 
RAJU 59 M " NO YES YES YES NO 84 140 80 N 6 MILD 2 8.7 2* 3 
NARAYANAN 62 M " YES NO YES NO NO 78 140 90 N 0 N 1 0.8 1 1 
VELU 47 M " YES NO YES NO YES 92 130 80 
AW 
ISCHEMIA 2 N 3 3.4 2* 1 
PERUMAL 62 M " YES NO YES NO NO 98 150 90 N 0 N 1 0.7 1 1 
KANNUSAMY 56 M " YES YES YES YES NO 94 140 90 N 5 N 2 4.7 2* 1 
KAMATCHI 60 F " YES NO NO NO NO 96 160 90 
AW 
ISCHEMIA 7 MILD 2 7.8 2* 3 
ARUMUGAM 56 M 
old 
AWMI YES NO YES NO NO 78 154 90 
AW 
ISCHEMIA 4 MILD 4 0.7 1 1 
VELAYUDHAM 42 M UA NO NO YES NO NO 72 130 80 N 0 N 1 0.7 1 1 
KRISHNAN 55 M " YES YES YES YES YES 82 140 100 
AW 
ISCHEMIA 5 MILD 3 7.8 2* 3 
MILLGI JOSEPH 62 F 
OLD 
IWMI YES NO NO NO NO 88 140 100 N 0 N 2 0.6 1 1 
SARAN 59 M 
OLD 
AWMI YES YES YES YES NO 92 160 90 
AW 
ISCHEMIA 6 MODERATE 4 1.3 1 1 
SAMPATH 47 M UA YES NO YES NO NO 74 130 80 IW ISCHEMIA 6 MILD 2 9 2* 3 
SREENIVASAN 54 M 
OLD 
IWMI NO YES YES NO NO 78 120 80 N 0 N 3 1.2 1 1 
SARASWATHY 58 F UA YES NO NO YES NO 96 140 90 N 0 N 2 2.6 1 1 
MOHAMMED 45 M " YES NO YES YES NO 92 140 90 N 0 MILD 2 3.7 2* 1 
RAMANI 48 F " YES NO NO NO NO 94 136 88 
AW 
ISCHEMIA 5 N 2 5.3 2* 1 
RAJENDRAN 52 M " NO YES YES NO NO 86 142 86 
AW 
ISCHEMIA 0 N 2 0.4 1 1 
RAJI 50 F 
OLD 
AWMI YES YES NO NO NO 78 140 90 
AW 
ISCHEMIA 7 MODERATE 4 8.7 2* 3 
ARUMUGAM 42 M UA YES NO YES YES NO 92 140 90 
AW 
ISCHEMIA 6 MILD 3 7.6 2* 3 
LALITHA BAI 49 F UA NO YES NO YES NO 84 140 80 N 0 N 1 0.8 1 1 
       
  
gr I 
M 
49.74 
70 M PREV CAD 
YES 
57 YES 34 YES 62 YES 44 YES 28 
GR I 
84.19 
GR I 
138.95
gr I 
86.24 GR I 13  MILD 21 
3 & 
ABOVE GR Ii 
gr 1 
42 GR I 1.02 
  
s.d 
10.05 22 F AWMI 12 
NO 
35 NO 58 NO 30 NO 48 NO 64 7.42 11.29 5.68 GR II 30 GR I  7 
3 to 
6=18
gr ii 
50 S.D 0.15 
  
sem 
1.55  IWMI 11  1.14 1.74 0.88 TOTAL 38 GR II 14 GR I   14
6 to 
9=24 SEM 0.02 
    
TOTAL 
23   21 9-12 =8
  
gr II 
51.32    
GR ii 
88.40
GR II 
142.24
Gr ii 
87.88 P=0.0067 MOD 10 GR II2.08 
  
s/d 
8.47  GR I  13  6.7 13.43 6.67 GR I  4 GR I 2.17
GR I 
1.207 0.85 
  
sem 
1.2  GR II 10  0.95 1.9 0.94 GR II 6 1.08 0.0719 0.12 
  
p=0.4
147     0.17 0.111 P=0001 
      
P=0.00
53
P=0.21
22
p=0.2
117 SEV 1 
       GR II 1 GRII 2.28
GR II 
6.654
  0.76 2.095 
  0.11 0.296 
            P=0.1290
            P=0.5182
 
 
MASTER CHART – II 
 
NAME GROUP HS CRP DIAGNOSIS 
LV 
FUNCTION CAG  
LAD LCX RCA SCORE NO CULPRIT A
 
READ 
MISSION 
Duration 
of stay 
RAGUPATHY 2* 10.3 UA N 1086 1-Feb MID 50 DIS OP 99 PDA 50 8 3VD LCX 2 
ANISHKUMAR 2* 10.3 " N 1104 9-Feb MID 90 ECC MID 90 P 50% 6 3VD LAD CABG 2 
CHINNASAMY 1 0.4 " N 1103 9-Feb MID 70 DIS N N 3 SVD LAD 1 
 MOHAN 2* 10.3 " N 1100 9-Feb N N N N NO N 3 
KUMARI 1 1.2 " N 1142 
19-
Feb N N N N N N   
1 
JOSEPH 2* 5.4 " MILD 1096 8-Feb PROX 50 DIS N N 3 SVD LAD 2 
ANTHONY 2* 6.2 old AWMI MILD 1107 
10-
Feb MID 9O DIS OM2 90 N 4 DVD LAD 
PTCA TO 
LAD  
3 
PANDIAN 2* 6.4 UA N 1106 
10-
Feb P99ECC N N 7 SVD LAD 
PTCA TO 
LAD  
3 
HARISHKUMAR 1 0.8 " N 1109 9-Feb n NIL NIL 0 N N 1 
CHINNASAMY 1 2 " N 1108 9-Feb N 
prox lcx 
70 N 3 SVD LCX 1 
SALEEMA BEE 2* 6.4 " N 1112 
11-
Feb MID 90 ECC N N 5 SVD LAD 
PTCA TO 
LAD UA 1 
TAMILARASAN 2* 4.8 " N 1110 
11-
Feb D1 50 N P 70 3 dvd RCA   
2 
ABDUL RAZAQ 2* 8 " N 1117 
12-
Feb N N M 90 4 SVD RCA   
3 
VEERANAM 1 1.8 " N 1121 
15-
Feb PROX 90 NIL N 4 SVD LAD 
PTCA TO 
LAD  
1 
PALANI 1 0.8 " N 1127 
16-
Feb N NIL N 0 n NIL   
1 
SAMUEL 2* 8.2 old AWMI MODERATE 1137 
18-
Feb P70DIS OM1 50 N 4 dvd LAD 
PTCA TO 
LAD  
2 
JEYACHANDRAN 1 2 OLD IWMI MILD 1132 
17-
Feb P 50 DIS NIL MID90 n dvd RCA  
UA 1 
MARIMUTHU 2* 8.2 OLD IWMI MODERATE 1134 
18-
Feb N OM70 MID 90 4 dvd RCA  
F 3 
LAKSHMANAN 2* 10.3 old AWMI MODERATE 1135 
18-
Feb D50 OM50 OP 99 7 tvd RCA  
F 3 
DAULATH BASHA 2* 7.5 UA N 1143 
20-
Feb N OM2 70 N 3 dvd LCX 
PTCA TO 
LAD MI 1 
RAVO 1 0.4 OLD IWMI MILD 1144 
21-
Feb N NIL N 0 n NIL 1 
INDIRANI 2* 6.4 UA MILD 1145 
21-
Feb D170 OM250 
PM 
LONG 90 7 tvd RCA UA 1 
SARASWATHY 2* 5.2 OLD IWMI MODERATE 1149 
21-
Feb P70EC N N 5 SVD LAD   
2 
HARIDOSS 2* 6.2 UA N 1148 
21-
Feb M70ECC N PDA 50 dvd LAD   
2 
BABUKANNAN 1 0.6 " N 1155 
23-
Feb N NIL NIL 0 n NIL   
1 
EDWARD JOSUA 2* 5.6 " N 1157 
23-
Feb N N N 0 n NIL   
2 
BABYAMMAL 1 1.2 OLD IWMI MILD 1161 
24-
Feb N NIL NIL 0 n NIL   
1 
MOHD IBRAHIM 2* 10.3 UA N 1162 
24-
Feb OP90 LS OM170 PLB70 7 tvd LAD CABG  
3 
ALPHONSE 1 2.6 " N 1169 
25-
Feb N NIL N 0 n NIL   
1 
ABDUL KHALID 2* 7.4 " N 1167 
25-
Feb M90 ECC D70 M50 5 tvd LAD MI 2 
vasudevan 1 0.7 " N 1170 
27-
Feb N NIL N 0 n NIL   
1 
SARASWATHY 2* 8.4 " MILD 1172 
27-
Feb D90ECCD2 P50 M50 6 tvd LAD  
UA 2 
RAMASAMY 2* 1.4 " N 1177 
28-
Feb N OM170 N 3 SVD LCX   
1 
RATHINAM 2* 8.4 " N 1180 
28-
Feb D50 N P90L 5 dvd RCA   
2 
RUKMANI 2* 4.8 " N 1183 2-Mar N N PDA70 3 SVD RCA 1 
GANDHI 1 0.8 " N 1186 2-Mar N NIL N 0 N NIL 1 
KANNAIYAN 2* 1.8 OLD AWMI SEVERE 1188 3-Mar D1 70 N N 3 SVD LAD 1 
GOVINDAN 2* 8.6 UA N 1191 4-Mar D 99 N P50 7 dvd LAD 3 
HANIFA 2* 7.8 OLD IWMI MODERATE 1195 4-Mar P90L P50 D50 7 td LAD 2 
AYESHA 1 0.8 UA N 1198 5-Mar N NIL N 0 N NIL 1 
RAJA 1 0.6 " N 1199 5-Mar N NIL N 0 N NIL 1 
SUBRAMANI 2* 6.2 " N 1200 6-Mar N N N 0 N NIL 3 
MALLIGA 1 2.8 " MILD 1205 6-Mar OP 90 LS OM1 70 P 70 ECC 7 tvd LAD CABG MI 1 
SIVABALAN 1 1.5 old AWMI MODERATE 1206 8-Mar N N 
MID 50 
DIS 2 SVD RCA   
1 
MAHENDRAN 1 0.5 OLD IWMI MODERATE 1208 8-Mar N NIL NIL 0 n NIL 1 
SUBRAMANI 2* 4 UA N 1212 9-Mar D50 OM190 N 5 dvd LCX 1 
MUNIAPPAN 2* 9.6 " N 1214 9-Mar P99ECC NIL NIL 7 SVD LAD 
PTCA TO 
LAD UA 3 
MAHENDRAN 2* 4.6 " N 1215 
10-
Mar N N M90ECC 5 SVD RCA 
PTCA TO 
RCA  
1 
CHANDRASEKAR 1 1 " N 1217 
10-
Mar N NIL NIL 0 n NIL   
1 
ANBU 1 2.3 old AWMI MILD 
cag no 
1224 
11-
Mar N NIL NIL 0 n NIL   
1 
SHEELA 2* 7.8 UA N cag 1223 
11-
Mar N N P90ECC 6 SVD RCA  
UA 3 
ELANGOVAN 1 0.7 " N cag 1229 
12-
Mar N N N 0 N NIL   
1 
SELVAM 2* 6.3 " N 1231 
12-
Mar P90ECC OM150 N 5 DVD LAD  
UA 3 
VASANTHA 1 1.3 OLD AWMI MODERATE cag 1238 
13-
Mar P 50 DIS P 70 DIS N 3 DVD LCX   
1 
SHANKAR 1 0.6 " N cag 1240 
15-
Mar N N N 0 N NIL   
1 
ANANDI 2* 3.8 " N cag 1242 
15-
Mar N N D90L 5 SVD RCA   
1 
ANGAMMAL 2* 10 " MILD cag 1246 
17-
Mar M50 P70 OP99L 8 TVD RCA CABG 3 
BABU 1 1 " N cag 1247 
17-
Mar N N N 0 N NIL   
1 
VASUDEVAN 2* 5.7 " N cag 1250 
17-
Mar P 90 LS D1 N PLB70 6 DVD LAD   
2 
RAMASAMY 2* 8.3 " MILD cag 1252 
18-
Mar D50 P90L PDA 70 6 TVD LCX   
3 
PILLAIYAPPAN 1 2.5 " N cag 1253 
18-
Mar N N N 0 N NIL   
2 
MASTHAN 1 2.6 " N cag 1258 
20-
Mar MID 50 DIS NIL 
MID 70 
TUB 4 DD RCA   
1 
ALAGUDURAI 1 0.4 " N cag 1259 
20-
Mar N N N 0 N NIL   
1 
ARUMUGAM 2* 4.8 OLD IWMI MILD 1260 
20-
Mar P90ECC N MID 50 5 DVD LAD 
PTCA TO 
LAD  
1 
KUMARI 2* 3.7 " N cag 1265 
22-
Mar N N N 0 N NIL   
1 
DOSS 1 1.3 OLD IWMI N cag 1270 
23-
Mar N N N 0 N NIL   
1 
SULTAN 1 1.3 UA N cag 1271 
23-
Mar N N N 0 N NIL   
1 
PUSHPA 2* 3.9 OLD AWMI MILD cag 1278 
24-
Mar M70D N N 3 SVD LAD 1 
BABU 1 0.6 OLD AWMI MILD cag 1282 
29-
Mar N N N 0 N NIL   
1 
SUBRAMANI 1 1.7 UA N cag 1281 
29-
Mar N N N 0 N NIL 1 
RAMAR 1 2.3 " N cag 1288 
30-
Mar N N N 0 N NIL   
1 
GOVARDHAN 2* 6 " N cag 1289 
30-
Mar N 50D M90ECC 5 DVD RCA 2 
RAJU 2* 8.7 " MILD 1293 
31-
Mar D90LON N N 6 SVD LAD 3 
NARAYANAN 1 0.8 " N 1295 
31-
Mar N N n 0 N NIL 1 
VELU 2* 3.4 " N 1 1-Apr N OM50 N 2 SVD LCX 1 
PERUMAL 1 0.7 " N 4 1-Apr N N N 0 N NIL 1 
KANNUSAMY 2* 4.7 " N 7 3-Apr D70ECC N PDA50 5 DVD LAD 1 
KAMATCHI 2* 7.8 " MILD 11 3-Apr M99ECC OM70 PDA70 7 TVD LAD CABG 3 
ARUMUGAM 1 0.7 old AWMI MILD 13 5-Apr D 70 TUB N PDA 70 4 DVD LAD 1 
VELAYUDHAM 1 0.7 UA N 14 5-Apr N N N 0 N NIL 1 
KRISHNAN 2* 7.8 " MILD 22 5-Apr MID 50 DIS N 
PR 70 
ECC 5 DVD RCA MI 3 
MILLGI JOSEPH 1 0.6 OLD IWMI N 23 6-Apr N N N 0 N NIL 1 
SARAN 1 1.3 OLD AWMI MODERATE 24 7-Apr MID 90 ECC OP 70 PDA  70 6 TVD LAD CABG 1 
SAMPATH 2* 9 UA MILD 25 7-Apr
P90 ECC NEAR 
D1 N PLB50 6 DVD LAD 3 
SREENIVASAN 1 1.2 OLD IWMI N 31 8-Apr N N N 0 N NIL 1 
SARASWATHY 1 2.6 UA N 32 8-Apr N N N 0 N NIL 1 
MOHAMMED 2* 3.7 " MILD 34 9-Apr N N N 0 N NIL 1 
RAMANI 2* 5.3 " N 37 9-Apr D70L N PDA70 5 DVD LAD 1 
RAJENDRAN 1 0.4 " N 42 
10-
Apr N N N 0 N NIL 1 
RAJI 
2* 8.7 OLD AWMI MODERATE 44 10-Apr D1 50 OM1 70 
P TO 
MID LS 
90 
7 TVD RCA   3 
ARUMUGAM 2* 7.6 UA MILD 46 
12-
Apr MID 90 LS N N 6 SVD LAD 3 
LALITHA BAI 1 0.8 UA N 54 
15-
Apr N N N 0 N NIL 1 
  
  gr 1 42 GR Ii PREV CAD MILD 21 
  gr ii 50 
3 to 
6=18 AWMI 12 GR I  7  CABG 6 UA 7 
   
6 to 
9=24 IWMI 11 GR II 14  
GR I  2 F2 
  9-12 =8 TOTAL 23 GR II 4 MI 3 
  MOD 10 
  GR I  4 
  GR II 6 PTCA 9 GR I 2 
  GR I 1 GR II 10 
  SEV 1 GR II 8 
 
